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Lungs with primary graft dysfunction (PGD) are characteristically edematous and have 
reduced compliance and impaired gas exchange. PGD is often attributed to ischemia–
reperfusion injury (IRI). Because IRI has been shown to cause alterations in the integrity of 
the endothelial barrier and alveolar epithelial capacity to resorb fluid,1,2 every transplanted 
lung is at risk of developing edema if there is any elevation of pulmonary venous pressure, 
either due to mechanical problems or left ventricular dysfunction. Previously, PGD has been 
attributed to events in the recipient, but pre-existing inflammatory status of the donor lung 
before recovery may also impact the development of PGD, as has been observed in brain-
dead donors or donors after circulatory death.3,4 Aside from early graft dysfunction, PGD is 
critically important due to its impact on long-term survival, because of the increased risk of 
bronchiolitis obliterans syndrome (BOS).5,6
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Our current theoretical understanding of the molecular triggers of PGD can be traced to 
ideas proposed by Polly Matzinger over 20 years ago.7 In her “Danger Hypothesis,” she 
proposed that endogenous substances (now categorized as damage-associated molecular 
patterns [DAMPs]) released from injured cells would promote innate immune responses that 
can prevent allograft survival.8 Janeway and Medzhitov showed that DAMPs, along with 
pathogen-associated molecule patterns (PAMPs), are recognized by pattern recognition 
receptors (PRRs) that, when engaged, stimulate inflammatory gene expression.9 Later 
reports showed DAMP accumulation and the involvement of PRR signaling pathways in 
PGD patients, but precisely how they contribute to this type of acute lung injury remains an 
active area of investigation,3,10,11 as lung IRI also may be influenced by PAMPs derived 
from the gut microbiota.12 In addition, the recent availability of multicenter-derived lung 
transplant recipient outcome data in conjunction with transcriptome and genomic analysis 
and new experimental approaches has identified additional mechanisms that could promote 
PGD. This has led to new insights into the role of the lung parenchyma, myeloid cells, 
lymphocytes, inflammatory mediators and autoreactive lung proteins. Moreover, there have 
been recent discoveries on how tissue inflammation is resolved, which, when applied to 
PGD, may provide the basis for the development of novel therapies. Herein we review the 
cellular and molecular mechanisms that mediate PGD.
Epithelium and endothelium
The inability to maintain and repair homeostatic barriers that promote pulmonary function, 
namely airway epithelium and vascular endothelium, is thought to play a key role in PGD. 
RNA transcript profiling experiments performed on 50 lungs before implantation analyzed 
differentially expressed transcripts between recipients with Grade 3 PGD at time of return to 
the intensive care unit (T0) and those that were Grade 0 PGD at T0.13 Of those 50 recipients, 
16 developed PGD Grade 3 at T0 and 34 were PGD negative at T0. Twenty-three genes were 
increased and 42 were decreased in the PGD group. A number of gene networks were 
identified that were involved in apoptosis and cellular stress responses. Metallothionein 3 
mRNA expression levels were higher in donor lungs that did not develop PGD. Those data 
suggest that donor lungs with more intact anti-oxidant defense and with a greater capability 
to support epithelial wound repair may be protected from PGD. However, because T0 PGD 
development may be related to intra-operative management, further studies will be needed to 
determine whether such gene expression patterns are linked to PGD severity at 72 hours 
post-transplant.
Collagen Type V (Col-V) is a constituent of the extracellular matrix and is usually hidden 
from exposure to the host immune system because it is contained entirely within Collagen 
Type I fibrils. Damage to the collagen structure in the lung can lead to exposure of Col-V, 
allowing it to act as a cryptic antigen that leads to autoimmunity against Col-V and a 
delayed-type hypersensitivity reaction. It has been suggested that pre-formed antibodies to 
Col-V in patients with advanced lung disease may predispose that individual to develop 
PGD after lung transplantation.14 Fifty-five patients awaiting lung transplant were 
investigated to assess their memory T-cell responses to Col-V. Sixteen had positive 
responses to Col-V. The positivity was much more frequent among idiopathic pulmonary 
fibrosis (IPF) patients (58.8%) compared to patients without IPF (15.8%). In a univariate 
Gelman et al. Page 2
J Heart Lung Transplant. Author manuscript; available in PMC 2018 April 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
analysis, T-cell responses to Col-V were associated with an increased risk of developing 
PGD. That study suggested that epithelium and endothelium basement membrane disruption 
in the donor lung may act as a trigger for T-cell–mediated immune responses in recipients 
pre-sensitized to Col-V.
Although endothelium and alveolar epithelium are targets of injury, they can also be sources 
of inflammatory mediators that may promote PGD. For example, studies have shown that 
ischemia, as a consequence of donor lung procurement, is mechanically sensed by 
endothelial cells, which respond by producing reactive oxygen species and nitric oxide that 
initiate pre-transplant tissue injury.15,16 The US Lung Transplant Outcomes Group 
compared plasma levels of 25 cytokines and chemokines in 25 recipients with Grade 3 PGD 
at 72 hours compared to 25 recipients without PGD at any time-point from 6 hours to 72 
hours as a nested case-control study.17 A multivariable logistic regression analysis showed 
that PGD cases had higher circulating levels of the chemokines monocyte chemoattractant 
protein-1/CC motif chemokine 2 (MCP-1/CCL2) and IP-10/CXC ligand 10, which can be 
secreted by activated endothelial cells and alveolar epithelial cells. That report suggested 
that an early chemotactic signal for monocytes and lymphocytes was present in lungs with 
PGD and that the activated endothelial or epithelial surfaces may have contributed to that 
signal. Notably, despite observations that cultured bronchial epithelial cells isolated from 
chronically rejected lung transplant recipients produced high amounts of inflammatory 
mediators,18 it remains to be determined whether bronchial epithelium plays a direct role in 
IRI-mediated cytokine production in PGD patients.
Toll-like receptor expression (TLR) on lung parenchymal cells may also play a major role in 
exacerbating PGD.19 TLR4, a PRR sensor for lipopolysaccharide (LPS) and damage-
associated molecular patterns released by injured cells, triggered early and sustained edema 
on non-bone-marrow-derived cells along with early activation of mitogen-activated protein 
kinases (MAPKs) and nuclear factor-kappaB (NF-κB) in a murine model of lung IRI. 
Endothelial cells subjected to simulated cold IRI suggested the possibility that edema due to 
IRI may be due to endothelial cell cytoskeletal alteration, thus leading to inter-endothelial 
cell gap formation during ischemia. Simulated reperfusion resulted in activation of MAPKs 
and NF-κB and expression of interleukin (IL)-6 and IL-8 by endothelial cells.20 In addition, 
in a cell culture model of simulated warm ischemia, inter-endothelial cell gap formation was 
prevented by a competitive TLR4 antagonist, implicating a direct link between pulmonary 
edema and TLR signaling.19
Angiotensin II (AngII) signaling has been implicated in the pathogenesis of pulmonary 
fibrosis. Moreover, inhibition of renin–angiotensin signaling has been shown to ameliorate 
experimental fibrous airway obliteration. In one study, there was an acute increase in plasma 
AngII and matrix metalloproteinase-9 (MMP-9) expression after lung transplantation, with a 
corresponding rise in angiotensin receptor 2 (ATR2) and tissue inhibitor of matrix metallo-
proteinase-1 (TIMP-1) expression on epithelial cells recovered from bronchoalveolar lavage 
fluid.21 Those data indicate that pro-fibrotic signals induced by ischemia-reperfusion and 
cardiopulmonary bypass may impair recovery of epithelial cell integrity.
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Pulmonary surfactant proteins produced by Type II pneumocytes are known to have major 
functions in host defense and lung immune homeostasis. Recipients of lung allografts with 
low levels of surfactant protein A (SP-A) mRNA expression before implantation had an 
increased incidence of Grades 2 or 3 PGD, higher 30-day mortality, and a greater likelihood 
of developing chronic lung allograft dysfunction (CLAD) or causing death within 24 months 
of transplant.22 Specifically, donor lungs with SP-A2 genotype 1A1A0 had the lowest level 
of SP-A messenger RNA (mRNA) expression.
The Clinical Trials in Organ Transplantation investigators sought to identify key pathways 
mediating PGD by comparing pre- and post-transplant donor lung bronchoalveolar lavage 
fluid (BALF) mRNA expression profiles in lung recipients who developed Grade 3 PGD 
versus controls matched for diagnosis and donor age who did not develop PGD.23 
Differential expression and gene set enrichment analysis identified inflammation activation 
and innate immune signaling via TLR pathways as major contributors to the pathogenesis of 
PGD. Those findings indicated an early innate immune signal in the lung, perhaps in 
response to inflammatory cytokines or DAMPs released by injured epithelial and endothelial 
cells.
Alveolar macrophages
PGD classically has been thought to be a biphasic process, with the first phase determined 
by donor cells and donor characteristics, whereas the infiltrating recipient cells were 
responsible for the second phase, which occurred within hours of reperfusion. The alveolar 
macrophage (AM) has been a known source of cytokines and oxidants in many models of 
acute inflammatory lung injury. AM depletion or inactivation reduced IRI in animal 
models.24–26 After ischemia and 15 minutes of reperfusion, tumor necrosis factor-alpha 
(TNF-α) and IL-1β localized to the AM and the early release allowed the AM to enhance 
the activation of other lung cell types.27–29 Therefore, AM activation and downstream 
signaling have been shown to be critical in the coordination and amplification of 
inflammatory signaling and development of lung reperfusion injury. More recently, the 
critical importance of TLR signaling in AM early in lung IRI has been recognized. Although 
the activating ligand is not yet known, within 15 minutes of reperfusion TLR4, through a 
signaling pathway that is dependent on the adapter protein myeloid differentiation factor 88 
(MyD88), promoted MAPK activation, nuclear translocation of NF-κB and transcriptional 
upregulation of inflammatory mediators.30 The same changes also occurred when AMs were 
isolated in culture and subjected to hypoxia and reoxygenation. The use of short-interfering 
RNA to knock down TLR4 expression in the AM markedly reduced the AM response to 
oxidative stress in vivo and in vitro.31 That signaling paradigm can be manipulated to take 
advantage of the dual nature of TLR4 signaling in the AM and provide protection from lung 
reperfusion injury. Low-dose LPS (which does not induce lung injury independently) can be 
administered to experimental animals intratracheally before lung ischemia and result in non-
ischemic pre-conditioning. Such LPS pre-treatment would inhibit AM TLR4 signaling 
through MyD88-dependent and -independent signaling pathways that utilize the adapter 
molecules toll-like/IL-1 receptor-domain-containing, adapter-inducing interferon-β (TRIF), 
and TRIF-related adapter molecule. The result enhanced AM production of interferon (IFN)-
γ and IL-10, reduced production of TNF-α and IL-1β and promoted lung protection.32 
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Notably, those findings from experimental models of lung IRI are consistent with recent 
human genomic studies of PGD.11,23
Neutrophils
Neutrophilia is thought to play a critical role in PGD.33 However, how neutrophils regulate 
PGD severity remains to be defined. The bulk of our understanding of this relationship has 
come from experimental lung injury models showing that the initial recruitment of 
neutrophils was triggered by DAMP release.34–37 As suggested by the “Danger Hypothesis” 
noted earlier, DAMPs stimulated cognate PRRs to induce the expression of ELR+ CXC 
chemokines and IL-1β, both of which were found to promote expression of adhesion 
molecules on the luminal surface of vascular endothelium to stimulate neutrophil 
transendothelial migration into interstitial tissues.38 In particular, early expression of 
IL-17,39 a well-established stimulator of ELR+ CXC chemokines,40 may play a critical role 
in early neutrophil graft sequestration.34 In a lung warm-ischemia model, the DAMP high-
mobility group box 1 (HMGB1) protein was recently shown to stimulate PRR, the receptor 
for advanced glycation products (RAGE) on invariant natural killer T cells, to produce IL-17 
and result in pulmonary neutrophilia. Consistent with these observations were reports 
showing that having either elevated RAGE plasma levels or carrying certain IL-17 receptor 
polymorphisms increased the risk for PGD.10,41
Grommes and Soehnlein showed that, after entry into the lung, neutrophils released reactive 
oxygen species (ROS), serine proteases, cationic peptides and MMPs that catalyzed the 
breakdown of homeostatic barriers that regulate blood gas exchange.42 For example, ROS 
have been shown to disrupt endothelial cell tight junctions and induce the necrosis of 
alveolar Type II cells, whereas the serine protease neutrophil elastase and the cationic 
peptide LL-37 have been shown to trigger epithelial cell apoptosis.43,44 In addition, MMPs, 
such as MMP-8, degraded the pulmonary collagen matrix.45,46 In addition to directly 
inflicting parenchymal tissue damage, neutrophils may promote PGD by directly inhibiting 
gas exchange through the expulsion of nuclear chromatin within the capillary lumen.47 The 
structures known as neutrophil extracellular traps (NETs) have recently been shown to 
accumulate in PGD patients.48
Given that the role of neutrophils in PGD is likely very complex, there has been considerable 
interest in developing better models of this injury. Introduction of the fully aerated and 
vascularized mouse orthotopic lung transplant (mOLT) model, which allows for the practical 
use of genetic dissection and transgene techniques, along with development of intravital lung 
2-photon microscopy to visualize and quantitate leukocyte trafficking, has led to new 
insights into how neutrophils promote inflammatory responses after lung 
transplantation.49,50 Importantly, when the mOLT was used to model PGD, there was a 
replication of the clinical scenario of neutrophilia, poor graft function and edema.51 Partial 
antibody-mediated depletion of neutrophils helped restore lung graft function and reduced 
tissue damage and inflammatory gene expression.52 That property of the model has led to 
further insights into how neutrophils promote PGD. These included the demonstration that 
the co-transcriptional factor B-cell lymphoma 3–encoded protein and the inhibitory κβ 
kinase β were negative regulators of lung transplant-mediated IRI through limiting 
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emergency granulopoiesis and attenuating neutrophil chemotactic mediator expression, 
respectively.52,53 In addition, neutrophil extravasation into graft interstitium was shown, 
unexpectedly, to be dependent on inflammatory monocytes,50 and intragraft neutrophils 
were observed making physical, prolonged contact with antigen-presenting cells to stimulate 
IL-12 expression and alloreactive Th1 cell expansion, suggesting a mechanism linking PGD 
to rejection.54 These data, taken collectively, may explain clinical reports of high levels of 
monocyte chemoattractants and IL-12 in PGD patients and the association between 
neutrophilia and rejection.17,55 Finally, the role of NETs in PGD patients was recently 
investigated using that model.48 Analogous to PGD patients, NETs were shown to 
accumulate in mOLT grafts. However, when mOLT recipients were treated with DNAse, 
pulmonary function improved significantly, suggesting a potential therapeutic approach for 
PGD.
Although neutrophils are predominantly recognized for their pro-inflammatory role in PGD, 
recent work has suggested that some level of neutrophilia is required to resolve tissue injury. 
For example, neutrophil swarming, which has been observed in lung transplant models of 
PGD, was reported to promote wound healing that will seal off damaged tissue.50 In 
addition, neutrophils through their own apoptotic death were found to play a critical role in 
re-establishing lung homeostasis after injury through the subsequent phagocytic uptake of 
their carcasses by lung macrophages.56 The clearance of apoptotic cells, efferocytosis, 
inhibited the production of IL-12 and induced the expression of anti-inflammatory mediators 
such as IL-10,57 a cytokine shown to promote the functional repair of human donor lungs 
when expressed ectopically.58 Future studies are needed to determine whether augmenting 
neutrophil efferocytosis may be useful as a therapeutic strategy to prevent PGD.
Lymphocytes
In a single lung transplant rat model, preservation with Perfadex solution primed with 
thioredoxin (Trx) showed significantly better graft function and attenuation of infiltration of 
macrophages and cytotoxic T cells compared with rats not primed with Trx.59 In mice, 
comparable and significant protection from lung dysfunction and injury occurred after 
antibody depletion of neutrophils or CD4+ T cells but not CD8+ T cells. Lung IRI was 
proportional to the infiltration of pulmonary neutrophils (PMNs) but not T cells. Moreover, 
PMN infiltration and the production of CXCL1/KC were significantly diminished by CD4+ 
T-cell depletion but not vice versa. That study suggested that PMNs mediated IRI; however, 
CD4+ T cells played a critical role in stimulating chemokine production and were 
responsible for neutrophil chemotaxis into the lung at the time of reperfusion.60
In a syngeneic rat lung transplant model,61 recipient CD4+ T cells infiltrated lung grafts 
within 1 hour of reperfusion and upregulated the expression of CD25 over the ensuing 12 
hours. After 12 hours of reperfusion, recipient nude rats demonstrated significantly better 
oxygenation and lower peak airway pressures than recipient heterozygous rats. The effect of 
T cells was independent of neutrophil recruitment and activation in the transplanted lung. 
The results demonstrated that recipient CD4+ T cells were activated and mediated lung 
injury 12 hours after lung transplantation in that model. The proliferation of the T cells was 
antigen-independent and is known as bystander activation.
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As noted earlier, pre-transplant activation of recipient immunity to Col-V may play a role in 
PGD after transplantation. Th17- and monocyte-dependent immunoreactivity directed 
toward Col-V has been associated with poor early lung allograft function and that reactivity 
was mediated by CD4+ T cells and monocytes. That finding supported the concept that 
humoral, as well as cell-mediated, immunity to Col-V is a risk factor for PGD, and that pre-
formed anti-Col-V antibodies have a key role in this process.14,62 Finally, increases in 
MCP-1 and CXCL10 in plasma of patients developing PGD, compared with controls, 
suggested that IFN-induced pathways resulted in accumulation of effector T cells in the 
allograft via CXCR3.60
Resolution and repair mechanisms
Although identification of the mechanisms of PGD mechanisms has been informative, 
translation to clinically effective therapies has been limited. This has led to increased interest 
into uncovering the determinants of resolution and repair after PGD. Resolution is not 
simply a passive process from removal of the initial insult and exhaustion of early 
inflammatory cells, but rather an active process. Resolution of PGD involves cellular and 
molecular pathways that involve: (a) removal of apoptotic neutrophils by macrophages; (b) 
reabsorption of protein and alveolar fluid; (c) repair of damaged endothelial and epithelial 
barrier; and (d) gradual clearance of extracellular matrix and fibrosis.
T lymphocytes have been ascribed, as a whole, to promote IRI,60 but more recent work has 
shown that a small fraction of CD4+ T cells, known as regulatory CD4+ T cells (Tregs), may 
play an opposite role.63 Identified by the expression of the master transcription factor 
forkhead box protein 3, Tregs promoted the maintenance of immunologic self-tolerance by 
suppressing aberrant or excessive immune responses that are harmful to the host.64,65 That 
function has been ascribed to inhibiting antigen-dependent responses, including 
experimental studies of immunosuppression-mediated lung transplant tolerance.66–68 
However, Tregs also have been reported to resolve experimental acute lung injury by 
inhibiting macrophage pro-inflammatory responses through augmenting neutrophil 
efferocytosis.69 Moreover, they have been shown to limit fibroproliferation and augment 
alveolar epithelial repair.70,71 Given their limited numbers, Tregs have been shown to 
become highly proliferative after lung inflammation and are a key feature in controlling 
exuberant immune responses.65,72 Ongoing clinical trials are evaluating the role of Tregs in 
solid-organ transplantation.73 Studies by Neujahr et al and Bhorade et al have shown that a 
decreased proportion of Foxp3+ cells among CD4 cells in bronchoalveolar lavage (BAL) can 
potentially predict worse lung allograft outcome and help guide therapeutic 
immunosuppression in lung transplant recipients.74,75 However, another group found that 
lung Tregs increased in the setting of acute rejection and declined in numbers in patients 
with quiescence of rejection.76 Therefore, the functional role of Tregs in humans with PGD 
remains elusive and there is a need to evaluate functional suppressive assays and rigorously 
phenotype sub-populations of Tregs in patients with PGD.
Other studies have suggested additional approaches to promote the resolution of PGD. 
Those studies included the recognition that resolution of tissue inflammation is a 
biosynthetically active process dependent on the synthesis of pro-resolving lipid 
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mediators.77 One such molecule, lipoxin A4, has been detected in lung transplant recipient 
BAL and has known potent inhibitory effects on neutrophil transendothelial migration.78 
Another lipid mediator, reslovin E1, was demonstrated to promote human neutrophil 
apoptosis and clearance of neutrophils from inflamed lungs in mice.79 Mesenchymal stem 
cells (MSCs), multipotent non-hematopoietic cells found in bone marrow and fatty tissues, 
have well-described immunosuppressive properties and have shown promise in ameliorating 
both acute and chronic pulmonary inflammation.80 Of note, in a recent report, conditioned 
media from bone-marrow-derived MSCs has been shown to induce Treg expansion and 
inhibit pulmonary edema in an experimental lung IRI model.81 Promoting endothelial 
integrity itself also may be a useful approach in combating PGD. Sphingosine 1-phosphate 
(S1P), a biologically active lipid growth factor that is derived from the cell membrane lipid 
component sphingosine, has been shown to bind to G-protein-coupled receptors that 
promote endothelial cell integrity.82 Reports in several lung IRI models, including a lung 
transplant-mediated IRI model, showed that FTY720, a functional analog of S1P, inhibited 
neutrophil sequestration, prevented edema and promoted pulmonary function.83,84 In 
addition, several pre-clinical studies have aimed at reducing tissue injury from ischemia and 
reperfusion by limiting ROS-mediated tissue injury. For example, allopurinol reduces of 
superoxide formation via inhibition of xanthine oxidase. Calcium channel blockers given to 
lung donors before organ procurement reduce lipid peroxidation and endothelial 
dysfunction, potentially limiting PGD. Iron chelators also limit lipid peroxidation and 
hydroxyl radical formation. Inhibitors of P-selectin, intracellular adhesion molecule-1 
(ICAM-1), C1 esterase, complement receptor 1 with selectin receptor (sialyl Lewis X), 
platelet-activating factor (PAF) and endothelin have shown benefit during lung IRI85–92 and 
may have similar effects in PGD. Inhibitors of complement receptor and PAF showed 
reductions in PGD in randomized, controlled trials.93,94 Studies using ex vivo lung perfusion 
systems will provide key translational data to facilitate development of new PGD therapies 
in the near future.
Conclusions
The last 10 years of investigation into the underlying mechanisms of PGD have illuminated 
important and novel roles for graft-infiltrating cells, graft-resident immune cells and 
parenchymal cells. In particular, the use of experimental PGD models has led to a working 
paradigm in which transplant-mediated innate immune signals generated by graft-resident 
cells, such as endothelium, epithelium and alveolar macrophages, trigger the overexuberant 
infiltration of monocytes, neutrophils and T cells. The crosstalk between these cells results 
in the release of cytokines, reactive oxygen intermediates and proteolytic enzymes that break 
down homeostatic barriers critical for lung graft function and the priming of adaptive 
immune responses that prevent transplant survival. Notably, risk for PGD may not be just 
intrinsically related to the graft, but may also be encoded into the recipient in the form of 
immune system-related genetic polymorphisms or pre-existing cellular or humoral reactivity 
to pulmonary autoantigens. However, the development of therapies to combat PGD 
ultimately may lie in better understanding of the mechanisms that promote the resolution of 
inflammation. Experimental models of acute lung injury and some clinical studies have 
suggested that strategies utilizing Tregs, augmenting efferocytosis or ameliorating oxidative 
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stress may be potential approaches to prevent or treat PGD. Although it appears that 
multiple pathways trigger and exacerbate PGD, what remains to be determined is which 
mechanisms are most important. To answer this question, it may be more advantageous to 
reverse the normal process of mechanistic investigation—that is, first determining whether 
observations from PGD patients can be reproduced in experimental models.
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